Your browser doesn't support javascript.
Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions.
Dudas, Gytis; Hong, Samuel L; Potter, Barney I; Calvignac-Spencer, Sébastien; Niatou-Singa, Frédéric S; Tombolomako, Thais B; Fuh-Neba, Terence; Vickos, Ulrich; Ulrich, Markus; Leendertz, Fabian H; Khan, Kamran; Huber, Carmen; Watts, Alexander; Olendraite, Ingrida; Snijder, Joost; Wijnant, Kim N; Bonvin, Alexandre M J J; Martres, Pascale; Behillil, Sylvie; Ayouba, Ahidjo; Maidadi, Martin Foudi; Djomsi, Dowbiss Meta; Godwe, Celestin; Butel, Christelle; Simaitis, Aistis; Gabrielaite, Migle; Katenaite, Monika; Norvilas, Rimvydas; Raugaite, Ligita; Koyaweda, Giscard Wilfried; Kandou, Jephté Kaleb; Jonikas, Rimvydas; Nasvytiene, Inga; Zemeckiene, Zivile; Gecys, Dovydas; Tamusauskaite, Kamile; Norkiene, Milda; Vasiliunaite, Emilija; Ziogiene, Danguole; Timinskas, Albertas; Sukys, Marius; Sarauskas, Mantas; Alzbutas, Gediminas; Aziza, Adrienne Amuri; Lusamaki, Eddy Kinganda; Cigolo, Jean-Claude Makangara; Mawete, Francisca Muyembe; Lofiko, Emmanuel Lokilo; Kingebeni, Placide Mbala; Tamfum, Jean-Jacques Muyembe.
  • Dudas G; Gothenburg Global Biodiversity Centre, Gothenburg, Sweden. gytisdudas@gmail.com.
  • Hong SL; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. gytisdudas@gmail.com.
  • Potter BI; Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
  • Calvignac-Spencer S; Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
  • Niatou-Singa FS; Epidemiology of Highly Pathogenic Organisms, Robert Koch Institute, 13353, Berlin, Germany.
  • Tombolomako TB; Viral Evolution, Robert Koch Institute, 13353, Berlin, Germany.
  • Fuh-Neba T; WWF Central African Republic Programme Office, Dzanga Sangha Protected Areas, BP 1053, Bangui, Central African Republic.
  • Vickos U; WWF Central African Republic Programme Office, Dzanga Sangha Protected Areas, BP 1053, Bangui, Central African Republic.
  • Ulrich M; WWF Central African Republic Programme Office, Dzanga Sangha Protected Areas, BP 1053, Bangui, Central African Republic.
  • Leendertz FH; Infectious and Tropical Diseases Unit, Department of medicine, Amitié Hospital, Bangui, Central African Republic.
  • Khan K; Academic Department of Pediatrics, Clinical immunology and vaccinology, Children's Hospital Bambino Gesù, IRCCS, Rome, Italy.
  • Huber C; Epidemiology of Highly Pathogenic Organisms, Robert Koch Institute, 13353, Berlin, Germany.
  • Watts A; Epidemiology of Highly Pathogenic Organisms, Robert Koch Institute, 13353, Berlin, Germany.
  • Olendraite I; BlueDot, Toronto, ON, M5J 1A7, Canada.
  • Snijder J; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, M5B 1A6, Canada.
  • Wijnant KN; Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, ON, M5S 3H2, Canada.
  • Bonvin AMJJ; BlueDot, Toronto, ON, M5J 1A7, Canada.
  • Martres P; BlueDot, Toronto, ON, M5J 1A7, Canada.
  • Behillil S; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Ayouba A; Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital Lab, CB2 2QQ, Cambridge, UK.
  • Maidadi MF; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH, Utrecht, The Netherlands.
  • Djomsi DM; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH, Utrecht, The Netherlands.
  • Godwe C; Bijvoet Centre for Biomolecular Research, Faculty of Science - Chemistry, Utrecht University, Padualaan 8, 3584 CH, Utrecht, The Netherlands.
  • Butel C; Microbiology, Centre Hospitalier René Dubos, Cergy Pontoise, France.
  • Simaitis A; Molecular Genetics of RNA viruses, CNRS UMR 3569, Université de Paris, Institut Pasteur, Paris, France.
  • Gabrielaite M; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Katenaite M; TransVIHMI, Université de Montpellier, IRD, INSERM, 911 Avenue Agropolis, 34394, Montpellier cedex, France.
  • Norvilas R; Centre de Recherches sur les Maladies Émergentes, Ré-émergentes et la Médecine Nucléaire, Institut de Recherches Médicales et D'études des Plantes Médicinales, Yaoundé, Cameroon.
  • Raugaite L; Centre de Recherches sur les Maladies Émergentes, Ré-émergentes et la Médecine Nucléaire, Institut de Recherches Médicales et D'études des Plantes Médicinales, Yaoundé, Cameroon.
  • Koyaweda GW; Centre de Recherches sur les Maladies Émergentes, Ré-émergentes et la Médecine Nucléaire, Institut de Recherches Médicales et D'études des Plantes Médicinales, Yaoundé, Cameroon.
  • Kandou JK; TransVIHMI, Université de Montpellier, IRD, INSERM, 911 Avenue Agropolis, 34394, Montpellier cedex, France.
  • Jonikas R; The Office of the Government of the Republic of Lithuania, Vilnius, Lithuania.
  • Nasvytiene I; Center for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Zemeckiene Z; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Gecys D; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Tamusauskaite K; Department of Experimental, Preventive and Clinical Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
  • Norkiene M; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Vasiliunaite E; Le Laboratoire National de Biologie Clinique et de Santé Publique (LNBCSP), Bangui, Central African Republic.
  • Ziogiene D; Le Laboratoire National de Biologie Clinique et de Santé Publique (LNBCSP), Bangui, Central African Republic.
  • Timinskas A; Department of Genetics and Molecular Medicine, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania.
  • Sukys M; Department of Genetics and Molecular Medicine, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania.
  • Sarauskas M; Department of Genetics and Molecular Medicine, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania.
  • Alzbutas G; Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Aziza AA; Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Lusamaki EK; Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Cigolo JM; Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Mawete FM; Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Lofiko EL; Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Kingebeni PM; Department of Genetics and Molecular Medicine, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania.
  • Tamfum JM; Department of Genetics and Molecular Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Nat Commun ; 12(1): 5769, 2021 10 01.
Article in English | MEDLINE | ID: covidwho-1447305
ABSTRACT
Distinct SARS-CoV-2 lineages, discovered through various genomic surveillance initiatives, have emerged during the pandemic following unprecedented reductions in worldwide human mobility. We here describe a SARS-CoV-2 lineage - designated B.1.620 - discovered in Lithuania and carrying many mutations and deletions in the spike protein shared with widespread variants of concern (VOCs), including E484K, S477N and deletions HV69Δ, Y144Δ, and LLA241/243Δ. As well as documenting the suite of mutations this lineage carries, we also describe its potential to be resistant to neutralising antibodies, accompanying travel histories for a subset of European cases, evidence of local B.1.620 transmission in Europe with a focus on Lithuania, and significance of its prevalence in Central Africa owing to recent genome sequencing efforts there. We make a case for its likely Central African origin using advanced phylogeographic inference methodologies incorporating recorded travel histories of infected travellers.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Randomized controlled trials Topics: Variants Limits: Humans Country/Region as subject: Africa / Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-26055-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Randomized controlled trials Topics: Variants Limits: Humans Country/Region as subject: Africa / Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-26055-8